Brief Introduction

Shanghai Shen Lian Biomedical Corporation was established in 2001. It is a high-tech enterprise, professional engaged in the R&D, production and sales of veterinary biological products. The main products are swine foot-and-mouth disease vaccine. Shen Lian Biomedical is China's first synthetic peptide vaccine manufacturer. The sales of the company's products rank first for more than ten years in the domestic market of synthetic peptide vaccine for foot-and-mouth disease.

While consolidating the advantage of the synthetic peptide vaccine for foot-and-mouth disease, the company is actively engaged in the R&D of the inactivated vaccine for foot-and-mouth disease. In 2017, the first domestic and foreign divalent inactivated vaccine for swine foot-and-mouth disease with type O and type A was successfully developed which obtained the national class-one new veterinary drug registration certificate. It enriched the company's product structure to enhance the company's market competitiveness.

After continuous research and development innovation,the company has get numerous R&D results and honors,including one National Grade II Prize of Science and Technology Progress and five New Veterinary Drug Registration Certificate and two of them are National Class-one.

Company Overview

Full name Shanghai Shen Lian Biomedical Corporation
Abbreviations Shen Lian Biomedical
Code 688098
Founded June 28,2001
Listing Octorber 28,2019
Domicile Shanghai
STAR Theme Biomedicine
CSRCSector Pharmaceutical manufacturing
Has weighted voting rights structure? No



  2018 2017 2016
Earnings Per Share 0.26 0.30 0.23
R&D expenditure as a % of operating revenue 7.74% 5.51% 6.26%
Operating Revenue 275 302 268
Net Income 88 99 73

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 275 302 268
Operating Costs 55 61 58
Operating Income 101 114 88
Pretax Income 10 116 91
Income Tax 88 99 73
Net Income 88 99 73

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Current Assets-Total 497 284 262
Non-current Assets-Total 516 409 346
Total Assets 1013 692 608
Current Liabilities-Total 151 119 142
Non-current Liabilities-Total 30 24 -
Total Liabilities 181 143 142
Stockholder's Equity
Share Capital 531 326 326
Retained Profits 301 223 139
Total Owners' Equity 832 549 465

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 121 75 48
Net Cash Flows-Investing -77 -103 -77
Net Cash Flows-Financing 196 12 29

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
杨玉芳 90.06 25.04%
杨从州 30.02 8.35%
苏州隆鼎创业投资企业(有限合伙) 20.92 5.82%
上海泓潮实业投资有限公司 20.92 5.82%
上海申太联投资合伙企业(有限合伙) 20.69 5.75%
王惠尚 18.91 5.26%
上海鼎太联投资合伙企业(有限合伙) 16.72 4.65%
海富长江成长股权投资(湖北)合伙企业(有限合伙) 13.74 3.82%
上海华贾投资有限公司 11.94 3.32%
30 Sep 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.